Literature DB >> 25784381

The impact of gout guidelines.

Eric Wise1, Puja P Khanna.   

Abstract

PURPOSE OF REVIEW: This review discusses the impact of recent treatment guidelines for the management of gout and the barriers to treating gout patients. RECENT
FINDINGS: Multiple guidelines for both the treatment and prevention of gout have been put forth in the last decade including those from the British Rheumatism Society; the European League Against Rheumatism; the Multinational Evidence, Expertise, Exchange Initiative; the Japanese Society of Gout and Nucleic Acid Metabolism; the American College of Rheumatology. These guidelines are designed to facilitate the management of gout by providers with key recommendations for the management of hyperuricemia, which is the greatest risk factor for developing gout. However, despite the extant guidelines, overall adherence to recommendations and uptake have been slow and initiation of urate-lowering therapy, titration of dosing, and monitoring of serum urate is infrequent. Greater education in proper management as well as increased awareness of new treatment strategies appear to be the primary reasons for this gap and offer avenues for improvement in management as well as areas for further research.
SUMMARY: Gout remains a treatment challenge for both acute and chronic disease. Despite the availability of management guidelines, primary care providers are struggling with appropriate management of the disease. More research tools and strategies are needed to improve overall outcomes and quality of care.

Entities:  

Mesh:

Year:  2015        PMID: 25784381     DOI: 10.1097/BOR.0000000000000168

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

1.  A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.

Authors:  Robert Goldfien; Alice Pressman; Alice Jacobson; Michele Ng; Andrew Avins
Journal:  Perm J       Date:  2016-07-01

2.  Study on Risk Factors of Diabetic Nephropathy in Obese Patients with Type 2 Diabetes Mellitus.

Authors:  Fan Hu; Taotao Zhang
Journal:  Int J Gen Med       Date:  2020-07-06

Review 3.  Treatment Options for Gout.

Authors:  Bettina Engel; Johannes Just; Markus Bleckwenn; Klaus Weckbecker
Journal:  Dtsch Arztebl Int       Date:  2017-03-31       Impact factor: 5.594

4.  Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.

Authors:  Janitzia Vazquez-Mellado; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Everardo Alvarez-Hernández; Sergio García-Méndez; Virginia Pascual-Ramos; Marina Rull-Gabayet
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

5.  Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Authors:  Thomas Bardin; Robert T Keenan; Puja P Khanna; Jeff Kopicko; Maple Fung; Nihar Bhakta; Scott Adler; Chris Storgard; Scott Baumgartner; Alexander So
Journal:  Ann Rheum Dis       Date:  2016-11-07       Impact factor: 19.103

6.  How patients with gout become engaged in disease management: a constructivist grounded theory study.

Authors:  Alyssa Howren; Susan M Cox; Kam Shojania; Sharan K Rai; Hyon K Choi; Mary A De Vera
Journal:  Arthritis Res Ther       Date:  2018-06-01       Impact factor: 5.156

7.  Diagnosis and treatment for hyperuricaemia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements.

Authors:  Qianrui Li; Xiaodan Li; Joey Sum-Wing Kwong; Hao Chen; Xin Sun; Haoming Tian; Sheyu Li
Journal:  BMJ Open       Date:  2017-06-23       Impact factor: 2.692

Review 8.  Relationship between hyperuricemia with deposition and sexual dysfunction in males and females.

Authors:  A Sansone; Y Reisman; E A Jannini
Journal:  J Endocrinol Invest       Date:  2022-01-08       Impact factor: 5.467

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.